Martin O'Dwyer

University of Glasgow, Glasgow, SCT, United Kingdom

Are you Martin O'Dwyer?

Claim your profile

Publications (4)6.48 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients who have had one oral cancer are at increased risk of developing a further malignant tumour, the detection of which is made difficult (and is often delayed) by the innocuous appearance of the early oral lesion. A technique that could reliably detect early cancers would be useful to both oral and dental health specialists. We describe a pilot study in which we used a compact spectroscopic instrument designed to excite and measure fluorescence in the oral cavity. The data were processed using principal components analysis, and the results suggest that the technique might be valuable for detecting early oral cancers. Further work should be performed to investigate some unusual characteristics observed within our data to ascertain if these are significant, simply due to errors made due data collection, or are due to other lifestyle factors. Such work could also verify that the data are due to detection of ALA metabolite in cancer and not some other systemic effect.
    British Journal of Oral and Maxillofacial Surgery 02/2008; 46(1):6-10. · 2.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients who have had one oral cancer are at increased risk of developing a semi-malignant tumour. The detecting of oral cancer is made difficult (and is often delayed) by the unknown appearance of the early oral lesion. A technique that could reliably detect early cancers would be useful to the oral and dental health specialist. One possible technique is the use of a photosensitiser that may be preferentially taken up by cancerous cells. 5-aminolaevulinic acid (ALA) is one such drug that is converted to Protoporphyrin IX (PpIX) and fluoresces at 636nm when illuminated with light of wavelength 405nm. It has been hypothesized that cell inclined towards malignant change would have a higher metabolic rate, and thus convert more ALA into its metabolite PpIX. These drugs can then be detected using a technique called Photodynamic detection, through the analysis of their fluorescence spectra. We describe a pilot study that used a compact spectroscopic instrument designed to excite and measure fluorescence in the oral cavity. Some Inter-subject variation in PpIX time course characteristics may be evident in our volunteers, as has been reported by other researchers. The obtained data would suggest that this instrument may be a valuable tool for detecting early oral cancers. However, further studies are required, not least to ensure that these data are due to detection of ALA metabolite in cancer and not some other systemic effect.
    Proc SPIE 03/2005;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Topical photodynamic therapy (PDT) is increasingly accepted and used as a highly effective treatment for superficial non-melanoma skin cancer and dysplasia. We describe the developments in topical PDT for the treatment of skin diseases in our own PDT Centre in Dundee, both clinically and from a research base. Improvements in PDT could be achieved by optimisation of photosensitiser and light delivery, and these goals underpin the aims of our centre. We hope to facilitate the dissemination of use of PDT in dermatology throughout Scotland and outline some of the progress in these areas.
    Photodiagnosis and Photodynamic Therapy 11/2004; 1:211-223. · 2.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, 5-aminolaevulinic acid (ALA) has become an increasingly popular photosensitizing drug for use in both photodynamic therapy (PDT) and photodetection (PD) of cancers. ALA metabolizes within tissue to form the photosensitizer protoporphyrin IX (PpIX). Like most photosensitizers, PpIX is fluorescent, and this fluorescence progressively decreases during PDT. This phenomenon is referred to as photobleaching. Our aim in carrying out this experiment was twofold: firstly, to compare the relative capacity of red and blue light to cause photobleaching; and secondly, to compare the capacity of a fixed light dose to cause photobleaching, when delivered at different intensities. In this paper, we describe the implementation of a compact fluorescence spectrometer in monitoring the photobleaching of ALA-induced PpIX in vivo on the skin of healthy volunteers. We have been able to show that blue light causes more rapid photobleaching than red light, and that under illumination with red or blue light, delivery of a fixed light dose at a lower intensity results in more photobleaching. Comparison of the photobleaching rates suggests that a blue light intensity of 5 mW/cm(2) gives the same rate of photobleaching as the typical red light PDT intensity of 100 mW/cm(2). Further investigation of the correlation between PpIX photobleaching and PDT effect would be beneficial in interpreting the clinical significance of our findings.
    Photodermatology Photoimmunology and Photomedicine 09/2004; 20(4):170-4. · 1.52 Impact Factor